HOME > Research


 
작성일 : 20-03-09 17:53
Effectiveness of a Fractionated Therapy Scheme in Tumor Treating Fields Therapy
 글쓴이 : 관리자
조회 : 2,636  

  This study aimed to evaluate the biological effectiveness of cancer therapy with tumor treating fields using a fractionated
treatment scheme that was originally designed for radiotherapy. Discontinuous fractional tumor treating fields of an intensity of
0.9 to 1.2 V/cm and a frequency of 150 KHz were applied to U373 cancer cells and IEC6 normal cells for 3 days, with durations of 3, 6, 12, or 24 h/d. As the treatment duration of the tumor treating fields increased from 3 to 24 h/d, the relative tumor cell (U373) number (% of control) reduced in proportion to the treatment duration. Compared to a 25% cell number reduction (75% of
control) for the group of 6 h/d treatment at 1.2 V/cm, only 5% (70% of control) and 8% (67% of control) of additional reductions
were observed for the group of 12 and 24 h/d treatment, respectively. This experimental result indicates that the dependence on
treatment duration in tumor cell inhibition was weakened distinctly at treatment duration over 6 h/d. For normal cells (IEC6), the
relative cell number corresponding to the treatment time of the tumor treating fields at 1.2 V/cm of electric field strength was not
decreased much for the treatment times of 3, 6, and 12 h/d, revealing 93.3%, 90.0%, and 89.3% relative cell numbers, respectively, but it suddenly decreased to *73% for the 24 h/d treatment. Our results showed that the effects of tumor treating fields on tumor cells were higher than on normal cells for treatment duration of 3 to 12 h/d, but the difference became minimal for treatment duration of 24 h/d. The fractionated scheme, using tumor treating fields, reduced the treatment time while maintaining efficacy, suggesting that this method may be clinically applicable for cancer treatment.

Yunhui Jo, BS1,2, Jiwon Sung, PhD1, Hyesun Jeong, MS3,
Sunghoi Hong, PhD3, Youn Kyoung Jeong, PhD4, Eun Ho Kim, PhD2, and
Myonggeun Yoon, PhD1

Technology in Cancer Research & Treatment
Volume 18: 1-10 The Author(s) 2019